FDA Cracks Eggs Over Safety Regs: Comment by April!
Published Date: 3/13/2026
Notice
Summary
The FDA is updating how it collects info about egg safety rules to keep food safe and healthy. This affects state and local food safety teams who help protect us from foodborne illnesses. They’re asking for your thoughts by April 13, 2026, to make sure the process is smooth and effective—no big cost changes expected!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
State and Tribal Reporting Burden Estimates
FDA estimates reporting burden per submission at 569 hours. For ERPS submissions FDA estimates 2 respondents, 1 response each, totaling 1,138 reporting hours; for AFRPS submissions FDA estimates 25 respondents, 1 response each, totaling 14,225 reporting hours; combined reporting burden is 15,363 hours. FDA also estimates annual recordkeeping burden totaling 11,800 hours (ERPS recordkeeping 800 hours; AFRPS recordkeeping 11,000 hours) and states there are no capital or operating and maintenance costs associated with this collection.
Revised Egg Safety Program Standards
The FDA revised the Egg Regulatory Program Standards (ERPS) to reflect lessons learned from the 2021 ERPS and updated program definitions, all 10 program standards, appendices, and assessment worksheets. States that have adopted ERPS will use the revised worksheets and forms, perform a baseline self-assessment in the first year of enrollment, and submit comprehensive reviews in subsequent years to verify conformance and improve program effectiveness and clarity.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20085, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Voluntary Improvement Program
The FDA is asking for public feedback by November 2, 2026, on its Voluntary Improvement Program (VIP), which helps medical device makers improve quality through third-party reviews. This program supports better products and safer devices without adding extra costs or deadlines for companies. It’s all about encouraging excellence and teamwork between the FDA, industry, and partners like the Medical Device Innovation Consortium.
Previous / Next Documents
Previous: 2026-04939, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Mammography Standards Quality Act Requirements
The FDA is asking for public feedback on renewing rules that keep mammogram centers safe and reliable. These rules affect mammography facilities, making sure their equipment, staff, and practices meet high standards. Comments are due by April 13, 2026, and this process helps protect patients without adding extra costs.
Next: 2026-04941, 2026 Environmental Financial Advisory Board (EFAB) Federal Advisory Committee Act (FACA) Charter 2-Year Renewal
The EPA is renewing the Environmental Financial Advisory Board (EFAB) for two more years to keep getting smart ideas on how to fund environmental and public health projects without spending extra taxpayer money. This board helps the EPA find ways to save money and attract private investments. The renewal keeps the board active through 2028 with a budget of about $287,000 per year.